ClinicalTrials.gg
CompletedNCT01463059Updated Mar 25, 2013

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

A Phase 2 interventional study of Placebo and Olokizumab 60 mg in Rheumatoid Arthritis, sponsored by UCB Japan Co. Ltd.. Completed at 39 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-03-25.

Sponsored by UCB Japan Co. Ltd. (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.

Enrollment
7th of 10
119 · median 206
Started
2011
with 1 other
Phase 2
4 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
1 of 10
UCB Japan Co. Ltd.

Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one is the 7th largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 2, and was the 4th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →

About olokizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing olokizumab in Arthritis, Rheumatoid as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy and safety of CDP6038 administered subcutaneous (sc) at various doses compared to placebo.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • Monoclonal Antibody
  • Interleukin-6
  • Olokizumab
  • CDP6038
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of adult-onset RA of at least 6 months' (24 weeks) duration as defined by the 1987 ACR classification criteria or a score of ≥6 as defined by the ACR/European League Against Rheumatism Classification and Diagnostic Criteria for RA
  • Must have moderately to severely active RA disease as defined by ≥6 tender joints (68-joint count) at Screening and Baseline, ≥6 swollen joints (66-joint count) at Screening and Baseline, CRP ≥1.2 times the (ULN) or ESR >28mm/hour
  • Must be on an MTX dose of 6 to 16mg/week in Japan or 7.5 to 20mg/week in Korea and Taiwan, which has been stable for at least 6 weeks prior to Screening with a stable route of administration
  • Must have had intolerance or inadequate response to treatment with 1 or more TNF-blocker therapies within 2 years of Screening
  • Female subjects must be either for at least 1 year, surgically incapable of childbearing, or effectively practicing 2 acceptable methods of

Exclusion criteria

Exclusion Criteria:

  • Have a diagnosis of any other inflammatory arthritis
  • Female subjects who are breast-feeding, pregnant, or plan to become pregnant during the study or within 24 weeks
  • Disease modifying antirheumatic drug (DMARDs) other than methotrexate (MTX)
  • Subjects with known concurrent acute or chronic viral or C infection
  • Subject has known tuberculosis (TB) disease, high risk of acquiring TB infection, or latent TB infection
  • Subjects with known history of or current clinically active infection
  • Subjects at high risk of infection
  • Subjects with known (HIV) or human T cell lymphotropic virus type 1 (HTLV 1) infection
  • Have received vaccinations within 8 weeks prior to Screening or plan to receive vaccines during the study (with the exception of injectable influenza and pneumococcal vaccinations which are permitted)
  • Concurrent or a history of malignancy (with the exception of successfully treated carcinoma of the cervix more than 5 years prior to Screening or no more than 2 successfully treated basal cell carcinomas within 2 years prior to Screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Placebo comparator
    Placebo every 2 weeks

    Injections administered at week 0, 2, 4, 6, 8 and 10

    Biological: Placebo

  • Experimental
    Olokizumab 60 mg every 2 weeks

    Olokizumab 60 mg injections administered at week 0, 2, 4, 6, 8 and 10

    Biological: Olokizumab 60 mg

  • Experimental
    Olokizumab 60 mg every 4 weeks

    Olokizumab 60 mg injection administered at week 0, 4, and 8 and Placebo injection administered at week 2, 6, and 10

    Biological: Placebo · Biological: Olokizumab 60 mg

  • Experimental
    Olokizumab 120 mg every 2 weeks

    Olokizumab 120 mg injections administered at week 0, 2, 4, 6, 8 and 10

    Biological: Olokizumab 120 mg

  • Experimental
    Olokizumab 120 mg every 4 weeks

    Olokizumab 120 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10

    Biological: Placebo · Biological: Olokizumab 120 mg

  • Experimental
    Olokizumab 240 mg very 4 weeks

    Olokizumab 240 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10

    Biological: Placebo · Biological: Olokizumab 240 mg

Interventions

  • BiologicalPlacebo

    Placebo solution for injection, administered as subcutaneous injections

  • Olokizumab 60 mg solution for injection, administered as subcutaneous injections

    Also known as: CDP6038

  • Olokizumab 120 mg solution for injection, administered as subcutaneous injections

    Also known as: CDP6038

  • Olokizumab 240 mg solution for injection, administered as subcutaneous injections

    Also known as: CDP6038

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Disease Activity Score 28-joint count (C-reactive protein) (DAS28[CRP]) at Week 12

    Time frame: From Week 0 (Baseline) to Week 12

Secondary outcomes

  1. Number of responders in American College of Rheumatology 20% Response Criteria (ACR20) at Week 12

    Number of subjects who achieve ACR 20 will be calculated at week 12. The calculation is based on the improvement from the baseline in the number of tender joints and in the number of swollen joints each; and the improvement based on assessments from the patient and the physician drawn according to defined standards.

    Time frame: From Week 0 (Baseline) to Week 12

  2. Number of responders in American College of Rheumatology 50% Response Criteria (ACR50) at Week 12

    Number of subjects who achieve ACR 50 will be calculated at week 12. The calculation is based on the improvement from the baseline in the number of tender joints and in the number of swollen joints each; and the improvement based on assessments from the patient and the physician drawn according to defined standards.

    Time frame: From Week 0 (Baseline) to Week 12

  3. Number of responders in American College of Rheumatology 70% Response Criteria (ACR70) at Week 12

    Number of subjects who achieve ACR 70 will be calculated at week 12. The calculations is based on the improvement from the baseline in the number of tender joints and in the number of swollen joints each; and the improvement based on assessments from the patient and the physician drawn according to defined standards.

    Time frame: From Week 0 (Baseline) to Week 12

07

Study locations

39 sites
  • 102
    Chiba, Japan
  • 114
    Fukuoka, Japan
  • 115
    Fukuoka, Japan
  • 113
    Hiroshima, Japan
  • 120
    Kakogawa, Japan
  • 118
    Kumamoto, Japan
  • 116
    Kurume, Japan
  • 121
    Matsuyama, Japan
  • 122
    Matsuyama, Japan
  • 107
    Nagaoka, Japan
  • 110
    Nagoya, Japan
  • 103
    Narita, Japan
  • 119
    Oita, Japan
  • 112
    Okayama, Japan
  • 100
    Sapporo, Japan
  • 117
    Sasebo, Japan
  • 124
    Tokorozawa, Japan
  • 123
    Tokyo, Japan
  • 101
    Tomakomai, Japan
  • 108
    Tonami, Japan
  • 111
    Tsu, Japan
  • 105
    Yokohama, Japan
  • 104
    Yotukaido, Japan
  • 200
    Daejeon, Korea, Republic of
  • 201
    Jung-gu, Korea, Republic of
  • 202
    Seongdong-gu, Korea, Republic of
  • 203
    Seoul, Korea, Republic of
  • 204
    Seoul, Korea, Republic of
  • 303
    Changhua, Taiwan
  • 304
    Dalin-Town, Taiwan
  • 305
    Hualien, Taiwan
  • 300
    Kaohsiung, Taiwan
  • 301
    Taichung, Taiwan
  • 306
    Taichung, Taiwan
  • 307
    Taichung, Taiwan
  • 302
    Taipei, Taiwan
  • 308
    Taipei, Taiwan
  • 309
    Taipei, Taiwan
  • 310
    Taipei, Taiwan
08

References and documents

Publications

  • Takeuchi T, Tanaka Y, Yamanaka H, Amano K, Nagamine R, Park W, Shiozawa K, Tsukano M, Wei JC, Shao J, Togo O, Mashimo H. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Mod Rheumatol. 2016;26(1):15-23. doi: 10.3109/14397595.2015.1074648. Epub 2015 Sep 10. Erratum In: Mod Rheumatol. 2018 Sep;28(5):911-912. doi: 10.1080/14397595.2018.1479049. PubMed 26358841 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2011
First posted
Nov 1, 2011
Start
Oct 2011
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results delay requested
Mar 19, 2013
Last update
Mar 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01463059
Lead sponsor
UCB Japan Co. Ltd.
Responsible party
Sponsor
First posted
Nov 1, 2011
Start date
Oct 2011
Primary completion
Feb 2013
Completion
Feb 2013
Last update
Mar 25, 2013

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olokizumab

Start the discussion